Bristol Myers assumed with a Neutral at Cantor Fitzgerald

Cantor Fitzgerald assumed coverage of Bristol Myers (BMY) with a Neutral rating and $55 price target Following the Cobenfy for schizophrenia approval and competitor muscarinic setbacks, Bristol’s underlying fundamentals have improved, but the critical question is whether there’s still room for upside after the recent move in shares with the stock up 43% since the start of July of last year, the analyst tells investors.